

Curriculum Vitae

Samira FAFI-KREMER



Date of Birth March 15, 1972, Meknes, Morocco,
French Nationality

Position

- Professor of Medicine – Attending Physician (PU-PH), Strasbourg University and Strasbourg University Hospitals, France
- Head of the Department of Medical Virology, Strasbourg University Hospitals
- Coordinator of Microbiology Department (PTM)
- Research Group Leader, Inserm Unit U1109, Labex TRANSPLANTEX, Strasbourg University

Appointments and Positions – Clinical

2018- Coordinator of Microbiology Department (PTM)
2015- Head of the Department of Medical Virology, Strasbourg University Hospitals
2013- Professor of Medicine– Attending Physician (PU-PH), Department of Medical Virology, Pole of Biology, Strasbourg University Hospitals, France
2011-2015 Head of the Unit of Molecular Microbiology, Strasbourg University Hospitals, France
2007-2013 Assistant Professor of Medicine-Attending Physician (MCU-PH), Department of Medical Virology, Pole of Biology, University Hospitals, Strasbourg
2005-2007 Resident (AHU), Department of Medical Virology, Pole of Biology, Strasbourg University Hospitals, France.
2001-2005 Resident (AHU), Department of Medical Virology, University Hospitals, Grenoble
1997-2001 Intern in “Pharmacie Spécialisée”, Faculty of Pharmacy, Joseph Fourier University, Grenoble, France

Appointments and Positions – Research

2014 Head of Research Team Inserm Unit U1109, Labex TRANSPLANTEX, Strasbourg University.
2011-2013 Coordinator of Translational Medicine Platform, Inserm Virology Unit U1110, Strasbourg University
2010- Research group leader, Inserm Virology Unit U1110, Labex “HEPSYS”, University of Strasbourg
2006-2009 Postdoc in Inserm Unit 748, “Virus-host interactions and liver disease”, Strasbourg University
2001-2005 Doctoral student, Joseph Fourier University, Grenoble, France.

Education

2014 Management Training, HEC Executive Education, HEC, Jouy-en Josas.
2009 Habilitation, Faculty of Medicine, University of Strasbourg, France
2005 University Thesis, Speciality « Bio-Technologie Santé et Management », Joseph Fourier University, Grenoble.
2004 Diplôme Universitaire de Pédagogie Médicale, Faculté de Médecine, Grenoble
2001 Doctor of Pharmacy, DES Pharmacie Spécialisée, DES Biologie Médicale, Joseph Fourier University, Grenoble, France
2000 Master research degree “Génie Biologique et Médical », Joseph Fourier University, Grenoble, France
1990-2001 University of Grenoble Pharmaceutical School
1989-1990 Faculty of Biology, Meknes, Morocco.
1989 Baccalauréat Section Sciences Expérimentales Bilingues, Morocco.

Teaching

Lectures and seminars in basic and medical virology:

- Strasbourg Medical School, Strasbourg, France
- Medical school of Jiaotong, Shanghai, China
- Master and PhD programs, University of Strasbourg, France
- Postgraduate education medical doctors, Strasbourg University Hospitals, France

Research supervision

- PhD students (7)
- Master 1 (15 students) et Master 2 recherche (12 students)

Reviewer for Scientific Journals

AIDS, Am J. Transplant., Exp. Rev. Mol. Diag., J. Clin. Virol., J. Med. Virol., J. Virol., Vaccine

Main publications

1. **Fafi-Kremer S**, Morand P, Brion JP, Pavese P, Baccard M, Germe R, Genoulaz O, Nicod S, Jolivet M, Ruigrok RW, Stahl JP, Seigneurin JM. Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. *J. Infect. Dis.*, 2005; **19**:985-9. (IF= 6,34)
2. **Fafi-Kremer S**, Morand P, Germe R, Ballout M, Brion JP, Genoulaz O, Nicod S, Stahl JP, Ruigrok R, and Seigneurin JM. A Prospective follow-up of Epstein-Barr Virus LMP-1 genotypes in saliva and blood during infectious mononucleosis. *J. Infect. Dis.*, 2005; **192**:2108-11. (IF= 6,34)
3. Payan C, Pivert A, Morand P, **Fafi-Kremer S**, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F, and the Scientific committee of ANRS HC02 RIBAVIC study. Early virological response in HIV/HCV co-infected patients to IFN or Peg-IFN plus Ribavirin assessed by HCV RNA. *Gut*, 2007; **56**:1111-6. (IF= 14,92)
4. **Fafi-Kremer S**, Stoll-Keller F, Baumert TF. Efficient postexposure prophylaxis by hepatitis A vaccine. *Hepatology*, 2008; **47**:1416-8. (IF= 11,71)
5. **Fafi-Kremer S**, Fofana I, Soulier E., Carolla P., Meuleman P., Leroux-Roels G., Patel A.H., Cosset F.L., Pessaux P., Doffoel M., Wolf P., Stoll-Keller F. and Baumert T. F. Escape from antibody-mediated neutralization and viral entry are key determinants for hepatitis C virus re-infection in liver transplantation. *J. Exp. Med.*, 2010, **207**, 2019-31. (IF=11,24)
6. Keymeulen B, Candon S, **Fafi-Kremer S**, Ziegler A, Lerulez-Ville M, Mathieu C, Vandemeulebroucke E, Walter M, Crenier L, Thervet E, Legendre C, Pierard D, Hale G, Waldmann H, Bach JF, Seigneurin JM, Pipeleers D, Chatenoud L. Transient Epstein Barr virus reactivation in CD3 monoclonal antibody-treated patients. *Blood*, 2010; **115**:1145-55. (IF= 11,84)
7. **Fafi-Kremer S**, Habersetzer F, Baumert TF. Hepatitis C virus entry and glucocorticosteroids. *J. Hepatol.*, 2010; **53**: 1148-50. (IF= 10,59)
8. Zeisel M, Fofana I, **Fafi-Kremer S**, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. *J. Hepatol.*, 2011; **54**:566-76. (IF= 10,59)
9. Lacey K*, Vercauteren K*, Grzyb K, Naddeo M Verhoye L, Słowikowski MP, **Fafi-Kremer S**, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. *J. Hepatol.*, 2012, **57**:17-23. (IF= 10,59)
10. Fofana I*, **Fafi-Kremer S***, Carolla P*, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Combet C, Hayer J, Cosset FL, Pietschmann T, Hiet MS, Bartenshlager R, Habersetzer F, Doffoel M, Keck ZY, Fong SKH, Zeisel MB, Stoll-Keller F, Baumert TF. (*: **Equally contributed**). Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. *Gastroenterology*, 2012; **143**:223-233. (IF= 18,18)
11. Desombere I*, **Fafi-Kremer S***, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-roels G, Baumert TF, Patel AH, Meuleman P (*: **Equally contributed**). Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. *Hepatology*, 2016; **63**, 1120-34. (IF=11,71)
12. Barth H, Solis M, Lepiller Q, Sueur C, Soulier E, Caillard S, Stoll-Keller F, **Fafi-Kremer S**. 45 years after the discovery of human polyomavirus BK and JC: Time to speed up the understanding of associated diseases and treatment approaches. *Crit. Rev. Microbiol.*, 2016; **1**, 1-18. (IF=8,19)
13. Solis M., Velay A., Porcher R., Pilar Domingo-Calap P., Soulier E., Joly M., Meddeb M., Kack-Kack W., Moulin B., Bahram S., Stoll-Keller F., Barth H., Caillard S., **Fafi-Kremer S**. Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. *J. Am. Soc. Nephrol.*, 2018, **29**, 326-334. (IF=8,98)
14. Martinot M, Ahle G, Petrosyan I, Martinez C, Gorun DM, Mohseni-Zadeh M, **Fafi-Kremer S**, Tebacher-Alt M. progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab. *Emerg Infect Dis.* 2018; **24**:1594-1596. (IF=7,42)
15. Gantner P, Lee GQ, Rey D, Mesplede T, Partisani M, Cheneau C, Beck-Wirth G, Faller JP, Mohseni-Zadeh M, Martinot M, Wainberg MA, **Fafi-Kremer S**. Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. *J Antimicrob Chemother.* 2018;**73**:1045-1053. (IF=5,22)
16. Velay A, Paz M, Cesbron M, Gantner P, Solis M, Soulier E, Argemi X, Martinot, M, Hansmann Y, **Fafi-Kremer S**. Tick-borne encephalitis virus: molecular determinants of neuropathogenesis of an emerging pathogen. *Crit Rev Microbiol.* 2019; **3**:1-22. (IF=8,19)